Macrophage mediated myofasciites: Current state of knowledge;Myofasciite à macrophages: État des connaissances

Revue Neurologique

Volumn 163, Issue 10, 2007, Pages 985-993

  Authier, F J ^a   Gherardi, R K ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; HEPATITIS A VACCINE; HEPATITIS B VACCINE;

DELTOID MUSCLE; ELECTROMYOGRAM; FRANCE; HISTOPATHOLOGY; HUMAN; MUSCLE BIOPSY; MUSCLE DISEASE; MYOFASCITIS; MYOSITIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; VACCINATION;

EID: 36248946825     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(07)92645-4     Document Type: Article

References (84)

1. ALONZO-RUIZ A, ZAS-MENDOZA AC, SALAZAR-VALLINAS JM, ROCAMORA-RIPOLL A, BELTRAN-GUTTIERREZ D. (1986). Toxic-oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Semin Arthritis Rheum, 15: 200-212.
2. Association E.M.M.M. Dossier : La myofasccite à macrophages. http://asso.e3m.free.fr/?page=dossierDetaille (accès le 03 Avril 2006).
3. AUTHIER FJ, CHERIN P, CREANGE A, BONNOTTE B, FERRER X, ABDELMOUMNI A et al. (2001). Central nervous system disease in patients with macrophagic myofasciitis. Brain, 124: 974-983.
4. AUTHIER FJ, LE BELLER Ch, BOUTOUYRIE P, LE LOUET H, GHERARDI RK, LAURENT S. (2005). Predictive score for macrophagic myofasciitis in vaccinees with chronic myalgias. Myology communication #396. http://www.myology2005. org/ (accès le 03 Avril 2006).
5. AUTHIER FJ, SAUVAT S, CHAMPEY J, DROGOU I, COQUET M, GHERARDI RK. (2003). Macrophagic myofasciitis as a cause of chronic fatigue syndrome. Arthritis Rheum, 48: 569-570.
6. 3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background. Neuromuscul Disord, 16: 347-352.
7. BASSEZ G, AUTHIER F-J, LECHAPT-Z ALCMAN E, DELFAU-LARUE M-H, PLONQUET A, COQUET M et al. (2003). Inflammatory myopathy with abundant macrophages (IMAM): a condition distinct from macrophagic myofasciitis, sharing similarities with cytophagic histiocytic panniculitis. J Neuropathol Exp Neurol, 62: 464-474.
8. BERGMANN JF. (2001). Faits, mensonges et « biblio ». Ann Med Int, 152 : 427-428.
9. BORNEMANN A, BOHL J, SCHNEIDER HM, GOEBEL HH, SCHMIDT PF, GHERARDI RK. (2004). July 2003: 62-year-old female with progressive muscular weakness. Brain Pathol, 14: 109-110.
10. BREWER JM, CONACHER M, HUNTER CA, MOHRS M, BROMBACHER F, ALEXANDER J. (1999). Aluminum hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4 and IL-13-mediated signaling. J Immunol, 163: 6448-6454.
11. BUCHWALD D, WENER MH, PEARLMAN T, KITH P. (1997). Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol, 24: 372-376.
12. CABELLO A, RUIZ-FALCÓ ML, GARCIA-PEÑA JJ, MADERO S, FERREIRO A, BAEZ B et al. (1999). Macrophagic myofasciitis: a new case of non-French origin [abstract]. Neuropathol Appl Neurobiol, 25: S44.
13. CASCIOLA-ROSEN L, WIGLEY F, ROSEN A. (1997). Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implication for pathogenesis. J Exp Med, 185: 71-80.
14. CHAO CC, GALLAGHER M, PHAIR J. (1990). Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis, 162: 1412-1413.
15. CHÉRIN P, AUTHIER FJ, GHERARDI RK, ROMERO N, LAFORÊT P, EYMARD B et al. (2000). Gallium-67 scintigraphy in macrophagic myofasciitis. Arthritis Rheum, 43: 1520-1526.
16. CHERIN P, GHERARDI RK, PENNAFORTE JL. (1999). Macrophagic myofasciitis: improvement with antibiotic therapy. J Rheumatol, 26: 2286-2287.
17. CHERIN P, MENARD D, MOUTON P, VIALLARD JF, LE HELLO C, AUTHIER FJ et al. (2001). Macrophagic myofasciitis associated with inclusion body myositis: a report of three cases. Neuromuscul Disord, 11: 452-457.
18. CHERRY N, CREED F, SILMAN A, DUNN G, BAXTER D, SMEDLEY J et al. (2001). Health and exposures of nited Kingdom Gulf war veterans. Part II. The relation of health to exposure. Occup Environ ed, 58: 299-306.
19. COKER WJ, BHATT BM, BLATCHLEY NF, GRAHAM JT. (1999). Clinical findings for the first 1000 Gulf war veterans in the Ministry of Defence's medical assessment programme. BMJ, 318: 290-294.
20. DALAKAS MC, ILLA I, PEZESHKPOUR GH, LAUKAITIS JP, COHEN B, GRIFFIN JL. (1990). Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med, 322: 1098-1105.
21. DEL GIUDICE G, PODDA A, RAPPUOLI R. (2002). What are the limits of adjuvanticity? Vaccine, 20: S38-S41.
22. DIMUNZIO A, CAPASSO M, VERROTTI A, TROTTA D, LUPO S, PAPPALEPORE N, MANZOLI C, CHIARELLI F, UNCINI A. (2004). Macrophagic myofasciitis: an infantile Italian case. Neuromuscul Disord, 14: 175-177.
23. FISCHER D, REIMANN J, SCHRODER R. (2003). [Macrophagic myofasciitis: inflammatory, vaccination-associated muscular disease]. Dtsch Med Wochenschr, 31; 128: 2305-2308.
24. FLAREND RE, HEM SL, WHITE JL, ELMORE D, SUCKOV MA, RUDY AC et al. (1997). In vivo absorption of aluminum-containing vaccine adjuvants using 26Al. Vaccine, 15: 1314-1318.
25. FOURNIÉ GJ, MAS M, CAUTAIN B, SAVIGNAC M, SUBRA JF, PELLETIER L et al. (2001). Induction of autoimmunity through bystander effects: lessons from immunological disorders induced by heavy metals. J Autoimmun, 16: 319-326.
26. FULLE S, MECOCCI P, FANO G. (2000). Specific oxidative alterations in vastus lateralis muscle of patients with diagnosis of chronic fatigue syndrome. Free Rad Biol Med, 29: 1252-1259.
27. GHERARDI RK, AUTHIER FJ. (2003). Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am, 23: 699-712.
28. GHERARDI RK, COQUET M, CHÉRIN P, AUTHIER FJ, LAFORÊT P, BELEC L et al. (1998). Macrophagic myofasciitis: an emerging entity. Lancet, 352: 347-352.
29. GHERARDI RK, COQUET M, CHERIN P, BELEC L, MORETTO P, DREYFUS PA et al. (2001a). Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminum hydroxide in muscle. Brain, 124: 1821-1831.
30. GHERARDI RK, PLONQUET A, ANDRÉ C, INTRATOR L, PORON MF, COQUET M et al. (2001b). Macrophagic myofasciitis: evidence for chronic local and systemic immune activation associated with persistence of aluminum hydroxide-loaded macrophages in muscle [abstract]. Neurology, 56(suppl 3): P01.121.
31. GHERARDI RK. (2003). Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant related syndrome. Rev Neurol (Paris), 159: 162-164.
32. GLENNY AT, POPE CG, WADDINGTON H, WALLACE UJ. (1926). The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol, 29: 31-40.
33. GUIS S, MATTEI JP, NICOLI F, PELLISSIER JF, KAPLANSKI G, FIGARELLA-B RANGER D et al. (2002a). Identical twins with macrophagic myofasciitis: genetic susceptibility and triggering by aluminic vaccine adjuvants? Arthritis Rheum, 47: 543-545.
34. GUIS S, PELLISSIER JF, NICOLI F, REVIRON D, MATTEI JP, GHERARDI RK et al. (2002b). HLA-DRB1*O1 and macrophagic myofasciitis. Arthritis Rheum, 46: 2535-2537.
35. GUPTA S, AGGARWAL S, SEE D, STARR A. (1997). Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res, 31: 149-156.
36. GUTTERIDGE JMC, QUINLAN GJ, CLARK I. (1985). Aluminum salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta, 835: 441-447.
37. HAMILTON JA, BYRNE R, WHITTY G. (2000). Particulate adjuvants can induce macrophage survival, DNA synthesis, and a synergistic proliferative response to GM-CSF and CSF-1. J Leukoc Biol, 67: 226-232.
38. HASSAN IS, BANNISTER BA, AKBAR A, WEIR W, BOFILL M. (1998). A study of the immunology of chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. Clin Immunol Immunopathol, 87: 60-67.
39. HELLIWELL TR, APPLETON RE, MAPSTONE NC, DAVIDSON J, WALSH KP. (2000). Dermatomyositis and Whipple's disease. Neuromusc Disord, 10: 46-51.
40. HENDRICK MJ, GOLDSCHMIDT MH, SHOFER FS, WANG YY, SOMLYO AP. (1992). Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res, 52: 5391-5394.
41. HERNAN MA, JICK SS, OLEK MJ, JICK H. (2004). Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology, 63: 838-842.
42. HORKKO S, MILLER E, DUDL E, REAVEN P, CURTISS LK, ZVAIFLER NJ et al. (1996). Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest, 98: 815-825.
43. HOTOPF M, DAVID A, HULL L, KHALIDA I, UNWIN C, WESSELY S. (2000). Role of vaccinations as risk factors for ill health in veterans of the Gulf war: cross sectional study. BMJ, 320: 1363-1367.
44. Institut de Veille Sanitaire (2001) Myofasciite à macrophages : rapport d'investigation exploratoire. Available at : http://www.invs.sante.fr.
45. JASON LA, WAGNER L, ROSENTHAL S. (1998). Estimating the prevalence of chronic fatigue syndrome among nurses. Am J Med, 105: 91S-93S.
46. KAUFMAN LD, SEIDMAN RJ, GRUBER BL. (1990). L-tryptophan-associated eosinophilic perimyositis, neuritis and fasciitis: a clinicopathologic and laboratory study of 25 patients. Medicine, 69: 187-199.
47. KONSTANTINOV K, VON MIKECZ A, BUCHWALD D, JONES J, GERACE L, TAN E. (1996). Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest, 98: 1888-1896.
48. LACSON AG, D'CRUZ CA, GILBERT-BARNESS E, SHARER L, JACINTO S, CUENCA R. (2002). Aluminum phagocytosis in quadriceps muscle following vaccination in children: relationship to macrophagic myofasciitis. Pediatr Dev Pathol, 5: 151-158.
49. LANDAY A, JESSOP C, LENETTE E, LEVY J. (1991). Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet, 338: 707-712.
50. MCDONALD KL, OSTERHOLM MT, LEDELL KH. (1997). A case-control study to assess possible triggers and cofactors in chronic fatigue syndrome. Am J Med, 100: 548-554.
51. MCCAULEY LA, JOOS SK, BARKHUIZEN A, SHUELL T, TYREE WA, BOURDETTE DN. (2002). Chronic fatigue in a populationbased study of Gulf War veterans. Arch Environ Health, 57: 340-348.
52. MCMAHON BJ, HELMINIAK C, WAINWRIGHT RB, BULKOW L, TRIMBLE BA, WAINWRIGHT K. (1992). Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med, 92: 254-256.
53. MAUBEC E, PINQUIER L, VIGUIER M, CAUX F, AMSLER E, ARACTINGI S, CHAFI H, JANIN A, CAYUELA JM, DUBERTRET L, AUTHIER FJ, BACHELEZ H. (2005). Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol, 52: 623-629.
54. MADEWELL BR, GRIFFEY SM, MCENTEE MC, LEPPERT VJ, MUNN RJ. (2001). Feline vaccine-associated fibrosarcoma: an ultrastructural study of 20 tumors (1996-1999). Vet Pathol, 38: 196-202.
55. MHIRI C, BAUDRIMONT M, BONNE G, GENY C, DEGOUL F, MARSAC C et al. (1991). Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol, 29: 606-614.
56. MISBAH SA, OZOLS B, FRANKS A, MAPSTONE N. (1997). Whipple's disease without malabsorption: new atypical features. Q J Med, 90: 765-772.
57. MITCHELL TC, HILDEMAN D, KEDL RM, TEAGUE TK, SCHAEFER BC, WHITE J et al. (2001). Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol, 5: 397-402.
58. NASCHITZ JE, JOCHANAN HB, MISSELEVICH I, YESHURUN D, ROSNER I. (1996). The fasciitispanniculitis syndromes: clinical and pathologic features. Medicine, 75: 6-16.
59. NEVO Y, KUTAI M, JOSSIPHOV, LIVNE A, NEEMAN Z, ARAD T, POPOVITZ-BIRO R, ATSMON J, SHAPIRA Y, SOFFER D. (2004). Childhood macrophagic myofasciitis-consanguinity and clinicopathological features. Neuromuscul Disord, 14: 246-252.
60. PAPO T. (2003). Macrophagic myofasciitis: focal or systemic. Joint Bone Spine, 70: 242-245.
61. PAPO T. (2005). Macrophagic myofasciitis: a new disease's paradigm? Rev Med Interne, 26: 175-178.
62. PARK JH, NA KS, PARK YW, PAIK SS, YOO DH. (2005). Macrophagic myofasciitis unrelated to vaccination. Scand J Rheumatol, 34: 65-67.
63. PATRARCA RA. (2001). Cytokines and chronic fatigue syndrome. Ann N Y Acad Sci, 933: 185-200.
64. Product insert for anthrax vaccine. Available at: http://www.dallasnw. quik.com/cyberella/Anthrax/Product.html.
65. REID S, CHALDER T, CLEARE A. (2000). Extracts from "Clinical Evidence": chronic fatigue syndrome. BMJ, 320: 292-296.
66. Report on the Working Group on the Possible Relationship between Hepatitis B Vaccination and the Chronic Fatigue Syndrome. (1993). Can Med Assoc J, 149: 314-316.
67. RIMANIOL AC, GRAS G, VERDIER F, CAPEL F, GRIGORIEV VB, PORCHERAY F et al. (2004). Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine, 22: 3127-3135.
68. SEEBER SJ, WHITE JL, HEM SL. (1991). Solubilization of aluminum containing adjuvants by constituents of interstitial fluid. J Parenter Sci Technol, 45: 156-159.
69. SHEPHARD RJ. (2002). Cytokine resonses to physical activity, with particular reference to IL6: sources, actions, and clinical implications. Crit Rev Immunol, 22: 165-182.
70. SHINDGE M, HUGHES J, BOADLE R, WILLS EJ, PAMPHLETT R. (2005). Macrophagic myofasciitis associated with vaccine-derived aluminium. Med J Aust, 183: 145-146.
71. SHIRODKAR S, HUTCHINSON RL, PERRY DL, WHITE JL, HEM SL. (1990). Aluminum compounds used as adjuvants in vaccines. Pharm Res, 7: 1282-1288.
72. SIMPSON DA. (2002). Systemic histiocytosis presenting as macrophagic myofasciitis. J Clin Neuromusc Dis, 4: 19-22.
73. SMITH LL. (2000). Cytokine hypothesis of overtraining: a physiological adaptation to excessive stress? Med Sci Sports Exerc, 32: 317-331.
74. TALBOT RJ, NEWTON D, PRIEST ND, AUSTIN JG, DAY JP. (1995). Intersubject variability in the metabolism of aluminum following intravenous injection as citrate. Hum Exp Toxicol, 14: 595-599.
75. TELLIER Ph. (2001). Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts. Ann Med Int, 152: 429-436.
76. TOURBAH A, LIBLAU R, LYON-CAEN O, BOUGNIOT C, IBA-ZIZEN MT, CABANIS EA. (1999). Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? Neurology, 53: 396-401.
77. ULANOVA M, TARKOWSKI A, HAHN-ZORIC M, HANSON LA. (2001). The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immunol, 69: 1151-1159.
78. Vaccine adverse reaction searchable database. Available at: http://www.fedbuzz.com/vaccine/vac.html.
79. VASCELLARI M, MELCHIOTTI E, BOZZA MA, MUTINELLI F. (2003). Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas. J Vet Med A Physiol Pathol Clin Med, 50: 286-291.
80. VERDIER F, BURNETT R, MICHELET-HABCHI C, MORETTO P, FIEVET-GROYNE F, SAUZEAT E. (2005). Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine, 23: 1359-1367.
81. WOLFE F, SMYTHE HA, YUNUS MB et al. (1990). The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum, 33: 160-172.
82. World Health Organization Vaccine Safety Advisory Committee. (1999). Macrophagic myofasciitis and aluminum-containing vaccines. Wkly Epidemiol Rec, 74: 338-340.
83. World Health Organization. (1976). Immunological adjuvants. In: Technical report series 595. Geneva: World Health Organization; p. 40.
84. YOSHINO M, ITO M, HANEDA M. (1999). Prooxidant action of aluminum ion: stimulation of iron-mediated lipid peroxidation by aluminum. Biometals, 12: 237-240.